NCT06672393View on ClinicalTrials.gov

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

October 22, 2025

Study Completion Date

June 29, 2026

Conditions
Psoriasis
Interventions
DRUG

HS-10374 6mg tablets

Specified dose of HS-10374 tablets administered orally QD on specified days

DRUG

HS-10374-matched placebo tablets

Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days

Trial Locations (1)

Unknown

Huashan Hospital affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY

NCT06672393 - A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter